Updated guidelines for chronic active Epstein–Barr virus disease

Chronic active Epstein–Barr virus disease (CAEBV), formerly named chronic active Epstein–Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein–Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagno...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2023-11, Vol.118 (5), p.568-576
Main Authors: Kawada, Jun-ichi, Ito, Yoshinori, Ohshima, Koichi, Yamada, Masaki, Kataoka, Shinsuke, Muramatsu, Hideki, Sawada, Akihisa, Wada, Taizo, Imadome, Ken-Ichi, Arai, Ayako, Iwatsuki, Keiji, Ohga, Shouichi, Kimura, Hiroshi
Format: Article
Language:English
Subjects:
Cell proliferation
Chemotherapy
Chronic infection
Copy number
Deoxyribonucleic acid
Diagnosis
Disease control
DNA
Epstein-Barr virus
Genomes
Guidelines
Health services
Hematology
Hematopoietic stem cells
Medicine
Medicine & Public Health
Oncology
Pathogenesis
Review
Review Article
Stem cell transplantation
Stem cells
Therapeutic applications
Transplantation
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c452t-51f1866ad5e8ec66f7440378227607a69b209278fb6a113f24acc199f2bf5363
cites cdi_FETCH-LOGICAL-c452t-51f1866ad5e8ec66f7440378227607a69b209278fb6a113f24acc199f2bf5363
container_end_page 576
container_issue 5
container_start_page 568
container_title International journal of hematology
container_volume 118
creator Kawada, Jun-ichi
Ito, Yoshinori
Ohshima, Koichi
Yamada, Masaki
Kataoka, Shinsuke
Muramatsu, Hideki
Sawada, Akihisa
Wada, Taizo
Imadome, Ken-Ichi
Arai, Ayako
Iwatsuki, Keiji
Ohga, Shouichi
Kimura, Hiroshi
description Chronic active Epstein–Barr virus disease (CAEBV), formerly named chronic active Epstein–Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein–Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagnosis and therapeutic interventions are necessary for favorable clinical outcomes. Substantial evidence regarding the pathogenesis and treatment of CAEBV has been accumulated since previous guidelines for the diagnosis of CAEBV were proposed. To reflect this evidence, we updated the guidelines for the diagnosis and treatment of CAEBV to improve clinical management of the disease. The details of the updated guidelines are presented in this report. Diagnosis of CAEBV now requires confirmation of a high copy number of EBV genome and EBV-infected T or NK cells. An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff value for CAEBV in this updated guideline. A standard treatment approach for CAEBV has not been established, and hematopoietic stem cell transplantation (HSCT) is considered the only curative treatment. Chemotherapy can be administered to control disease activity before HSCT.
doi_str_mv 10.1007/s12185-023-03660-5
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10615970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2866758077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-51f1866ad5e8ec66f7440378227607a69b209278fb6a113f24acc199f2bf5363</originalsourceid><addsrcrecordid>eNp9kc1KxDAUhYMoOo6-gKuCGzfVm6RJ2pXo4B8IbsZ1yKQ3Y6TTjkk74M538A19EqMjii5c3Qv3O4dzOYQcUDimAOokUkZLkQPjOXApIRcbZERLKXKuVLFJRlAxkQtFYYfsxvgIQBUUapvspDsr0z4i5_fL2vRYZ_PB19j4FmPmupDZh9C13mbG9n6F2cUy9ujbt5fXcxNCtvJhiFntI5qIe2TLmSbi_tcck-nlxXRynd_eXd1Mzm5zWwjW54K6lE2aWmCJVkqnigK4KhlTEpSR1YylvKp0M2ko5Y4VxlpaVY7NnOCSj8np2nY5zBZYW2z7YBq9DH5hwrPujNe_L61_0PNupSlIKioFyeHoyyF0TwPGXi98tNg0psVuiJqleEqUoFRCD_-gj90Q2vReoirgRUWrD0O2pmzoYgzovtNQ0B8V6XVFOlWkPyvSIon4WhQT3M4x_Fj_o3oHOq2SrQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890349190</pqid></control><display><type>article</type><title>Updated guidelines for chronic active Epstein–Barr virus disease</title><source>Springer Nature</source><creator>Kawada, Jun-ichi ; Ito, Yoshinori ; Ohshima, Koichi ; Yamada, Masaki ; Kataoka, Shinsuke ; Muramatsu, Hideki ; Sawada, Akihisa ; Wada, Taizo ; Imadome, Ken-Ichi ; Arai, Ayako ; Iwatsuki, Keiji ; Ohga, Shouichi ; Kimura, Hiroshi</creator><creatorcontrib>Kawada, Jun-ichi ; Ito, Yoshinori ; Ohshima, Koichi ; Yamada, Masaki ; Kataoka, Shinsuke ; Muramatsu, Hideki ; Sawada, Akihisa ; Wada, Taizo ; Imadome, Ken-Ichi ; Arai, Ayako ; Iwatsuki, Keiji ; Ohga, Shouichi ; Kimura, Hiroshi ; The Committee for Guidelines for the Management of Chronic Active EBV Disease, Related Disorders (the MHLW Research Team in Japan)</creatorcontrib><description>Chronic active Epstein–Barr virus disease (CAEBV), formerly named chronic active Epstein–Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein–Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagnosis and therapeutic interventions are necessary for favorable clinical outcomes. Substantial evidence regarding the pathogenesis and treatment of CAEBV has been accumulated since previous guidelines for the diagnosis of CAEBV were proposed. To reflect this evidence, we updated the guidelines for the diagnosis and treatment of CAEBV to improve clinical management of the disease. The details of the updated guidelines are presented in this report. Diagnosis of CAEBV now requires confirmation of a high copy number of EBV genome and EBV-infected T or NK cells. An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff value for CAEBV in this updated guideline. A standard treatment approach for CAEBV has not been established, and hematopoietic stem cell transplantation (HSCT) is considered the only curative treatment. Chemotherapy can be administered to control disease activity before HSCT.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-023-03660-5</identifier><identifier>PMID: 37728704</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Cell proliferation ; Chemotherapy ; Chronic infection ; Copy number ; Deoxyribonucleic acid ; Diagnosis ; Disease control ; DNA ; Epstein-Barr virus ; Genomes ; Guidelines ; Health services ; Hematology ; Hematopoietic stem cells ; Medicine ; Medicine &amp; Public Health ; Oncology ; Pathogenesis ; Review ; Review Article ; Stem cell transplantation ; Stem cells ; Therapeutic applications ; Transplantation ; Viruses</subject><ispartof>International journal of hematology, 2023-11, Vol.118 (5), p.568-576</ispartof><rights>The Author(s) 2023</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-51f1866ad5e8ec66f7440378227607a69b209278fb6a113f24acc199f2bf5363</citedby><cites>FETCH-LOGICAL-c452t-51f1866ad5e8ec66f7440378227607a69b209278fb6a113f24acc199f2bf5363</cites><orcidid>0000-0003-1553-2539</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids></links><search><creatorcontrib>Kawada, Jun-ichi</creatorcontrib><creatorcontrib>Ito, Yoshinori</creatorcontrib><creatorcontrib>Ohshima, Koichi</creatorcontrib><creatorcontrib>Yamada, Masaki</creatorcontrib><creatorcontrib>Kataoka, Shinsuke</creatorcontrib><creatorcontrib>Muramatsu, Hideki</creatorcontrib><creatorcontrib>Sawada, Akihisa</creatorcontrib><creatorcontrib>Wada, Taizo</creatorcontrib><creatorcontrib>Imadome, Ken-Ichi</creatorcontrib><creatorcontrib>Arai, Ayako</creatorcontrib><creatorcontrib>Iwatsuki, Keiji</creatorcontrib><creatorcontrib>Ohga, Shouichi</creatorcontrib><creatorcontrib>Kimura, Hiroshi</creatorcontrib><creatorcontrib>The Committee for Guidelines for the Management of Chronic Active EBV Disease, Related Disorders (the MHLW Research Team in Japan)</creatorcontrib><title>Updated guidelines for chronic active Epstein–Barr virus disease</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>Chronic active Epstein–Barr virus disease (CAEBV), formerly named chronic active Epstein–Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein–Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagnosis and therapeutic interventions are necessary for favorable clinical outcomes. Substantial evidence regarding the pathogenesis and treatment of CAEBV has been accumulated since previous guidelines for the diagnosis of CAEBV were proposed. To reflect this evidence, we updated the guidelines for the diagnosis and treatment of CAEBV to improve clinical management of the disease. The details of the updated guidelines are presented in this report. Diagnosis of CAEBV now requires confirmation of a high copy number of EBV genome and EBV-infected T or NK cells. An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff value for CAEBV in this updated guideline. A standard treatment approach for CAEBV has not been established, and hematopoietic stem cell transplantation (HSCT) is considered the only curative treatment. Chemotherapy can be administered to control disease activity before HSCT.</description><subject>Cell proliferation</subject><subject>Chemotherapy</subject><subject>Chronic infection</subject><subject>Copy number</subject><subject>Deoxyribonucleic acid</subject><subject>Diagnosis</subject><subject>Disease control</subject><subject>DNA</subject><subject>Epstein-Barr virus</subject><subject>Genomes</subject><subject>Guidelines</subject><subject>Health services</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Pathogenesis</subject><subject>Review</subject><subject>Review Article</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Therapeutic applications</subject><subject>Transplantation</subject><subject>Viruses</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kc1KxDAUhYMoOo6-gKuCGzfVm6RJ2pXo4B8IbsZ1yKQ3Y6TTjkk74M538A19EqMjii5c3Qv3O4dzOYQcUDimAOokUkZLkQPjOXApIRcbZERLKXKuVLFJRlAxkQtFYYfsxvgIQBUUapvspDsr0z4i5_fL2vRYZ_PB19j4FmPmupDZh9C13mbG9n6F2cUy9ujbt5fXcxNCtvJhiFntI5qIe2TLmSbi_tcck-nlxXRynd_eXd1Mzm5zWwjW54K6lE2aWmCJVkqnigK4KhlTEpSR1YylvKp0M2ko5Y4VxlpaVY7NnOCSj8np2nY5zBZYW2z7YBq9DH5hwrPujNe_L61_0PNupSlIKioFyeHoyyF0TwPGXi98tNg0psVuiJqleEqUoFRCD_-gj90Q2vReoirgRUWrD0O2pmzoYgzovtNQ0B8V6XVFOlWkPyvSIon4WhQT3M4x_Fj_o3oHOq2SrQ</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Kawada, Jun-ichi</creator><creator>Ito, Yoshinori</creator><creator>Ohshima, Koichi</creator><creator>Yamada, Masaki</creator><creator>Kataoka, Shinsuke</creator><creator>Muramatsu, Hideki</creator><creator>Sawada, Akihisa</creator><creator>Wada, Taizo</creator><creator>Imadome, Ken-Ichi</creator><creator>Arai, Ayako</creator><creator>Iwatsuki, Keiji</creator><creator>Ohga, Shouichi</creator><creator>Kimura, Hiroshi</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1553-2539</orcidid></search><sort><creationdate>20231101</creationdate><title>Updated guidelines for chronic active Epstein–Barr virus disease</title><author>Kawada, Jun-ichi ; Ito, Yoshinori ; Ohshima, Koichi ; Yamada, Masaki ; Kataoka, Shinsuke ; Muramatsu, Hideki ; Sawada, Akihisa ; Wada, Taizo ; Imadome, Ken-Ichi ; Arai, Ayako ; Iwatsuki, Keiji ; Ohga, Shouichi ; Kimura, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-51f1866ad5e8ec66f7440378227607a69b209278fb6a113f24acc199f2bf5363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cell proliferation</topic><topic>Chemotherapy</topic><topic>Chronic infection</topic><topic>Copy number</topic><topic>Deoxyribonucleic acid</topic><topic>Diagnosis</topic><topic>Disease control</topic><topic>DNA</topic><topic>Epstein-Barr virus</topic><topic>Genomes</topic><topic>Guidelines</topic><topic>Health services</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Pathogenesis</topic><topic>Review</topic><topic>Review Article</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Therapeutic applications</topic><topic>Transplantation</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawada, Jun-ichi</creatorcontrib><creatorcontrib>Ito, Yoshinori</creatorcontrib><creatorcontrib>Ohshima, Koichi</creatorcontrib><creatorcontrib>Yamada, Masaki</creatorcontrib><creatorcontrib>Kataoka, Shinsuke</creatorcontrib><creatorcontrib>Muramatsu, Hideki</creatorcontrib><creatorcontrib>Sawada, Akihisa</creatorcontrib><creatorcontrib>Wada, Taizo</creatorcontrib><creatorcontrib>Imadome, Ken-Ichi</creatorcontrib><creatorcontrib>Arai, Ayako</creatorcontrib><creatorcontrib>Iwatsuki, Keiji</creatorcontrib><creatorcontrib>Ohga, Shouichi</creatorcontrib><creatorcontrib>Kimura, Hiroshi</creatorcontrib><creatorcontrib>The Committee for Guidelines for the Management of Chronic Active EBV Disease, Related Disorders (the MHLW Research Team in Japan)</creatorcontrib><collection>Springer Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawada, Jun-ichi</au><au>Ito, Yoshinori</au><au>Ohshima, Koichi</au><au>Yamada, Masaki</au><au>Kataoka, Shinsuke</au><au>Muramatsu, Hideki</au><au>Sawada, Akihisa</au><au>Wada, Taizo</au><au>Imadome, Ken-Ichi</au><au>Arai, Ayako</au><au>Iwatsuki, Keiji</au><au>Ohga, Shouichi</au><au>Kimura, Hiroshi</au><aucorp>The Committee for Guidelines for the Management of Chronic Active EBV Disease, Related Disorders (the MHLW Research Team in Japan)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Updated guidelines for chronic active Epstein–Barr virus disease</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><date>2023-11-01</date><risdate>2023</risdate><volume>118</volume><issue>5</issue><spage>568</spage><epage>576</epage><pages>568-576</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Chronic active Epstein–Barr virus disease (CAEBV), formerly named chronic active Epstein–Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein–Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagnosis and therapeutic interventions are necessary for favorable clinical outcomes. Substantial evidence regarding the pathogenesis and treatment of CAEBV has been accumulated since previous guidelines for the diagnosis of CAEBV were proposed. To reflect this evidence, we updated the guidelines for the diagnosis and treatment of CAEBV to improve clinical management of the disease. The details of the updated guidelines are presented in this report. Diagnosis of CAEBV now requires confirmation of a high copy number of EBV genome and EBV-infected T or NK cells. An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff value for CAEBV in this updated guideline. A standard treatment approach for CAEBV has not been established, and hematopoietic stem cell transplantation (HSCT) is considered the only curative treatment. Chemotherapy can be administered to control disease activity before HSCT.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>37728704</pmid><doi>10.1007/s12185-023-03660-5</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1553-2539</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0925-5710
ispartof International journal of hematology, 2023-11, Vol.118 (5), p.568-576
issn 0925-5710
1865-3774
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10615970
source Springer Nature
subjects Cell proliferation
Chemotherapy
Chronic infection
Copy number
Deoxyribonucleic acid
Diagnosis
Disease control
DNA
Epstein-Barr virus
Genomes
Guidelines
Health services
Hematology
Hematopoietic stem cells
Medicine
Medicine & Public Health
Oncology
Pathogenesis
Review
Review Article
Stem cell transplantation
Stem cells
Therapeutic applications
Transplantation
Viruses
title Updated guidelines for chronic active Epstein–Barr virus disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A37%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Updated%20guidelines%20for%20chronic%20active%20Epstein%E2%80%93Barr%20virus%20disease&rft.jtitle=International%20journal%20of%20hematology&rft.au=Kawada,%20Jun-ichi&rft.aucorp=The%20Committee%20for%20Guidelines%20for%20the%20Management%20of%20Chronic%20Active%20EBV%20Disease,%20Related%20Disorders%20(the%20MHLW%20Research%20Team%20in%20Japan)&rft.date=2023-11-01&rft.volume=118&rft.issue=5&rft.spage=568&rft.epage=576&rft.pages=568-576&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-023-03660-5&rft_dat=%3Cproquest_pubme%3E2866758077%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-51f1866ad5e8ec66f7440378227607a69b209278fb6a113f24acc199f2bf5363%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2890349190&rft_id=info:pmid/37728704&rfr_iscdi=true